• WHITTEMORE PETERSON INSTITUTE FOR NEURO-IMMUNE DISEASE



Translational Research Towards the Diagnosis of Difficult Medical Cases of ME/CFS

Judy A. Mikovits, PhD

May 29, 2009



I not only use all the brains that I have, but all that I can borrow. Woodrow Wilson

Nevada CFS Cohort:

Between 1984 and 1987, a cluster of 300 cases of CFS was identified in Incline Village Nevada. Recently, a subset of the Nevada CFS cohort (77 to date) have presented with clonal T Cell receptor gamma rearrangements. This abnormality is suggestive of a persistent infection and predicative of the development of lymphoma. For these studies, we isolated RNA, DNA and plasma From ~100 of this cohort at two time points Sept 06 and July 07



Viral Microarray Profiling:



Cancer Inflammation Program Francis W. Ruscetti, PhD

<u>Advanced Biomedical Computing</u> <u>Center</u> Ming Yi, PhD Robert M. Stephens, PhD



Judy A Mikovits, PhD

Daniel L. Peterson MD

Darren White

Kathryn Hagen

David Pomeranz

The Patients of Sierra Internal Medicine!

<u>Advanced Viral Technology</u> <u>Program</u> Rachel K. Bagni, PhD



Problem: Prior to this study no study has been able to address the expression of all viruses in a single sample from a CFS population with immunological phenotypes suggesting a chronic active viral infection.

- We addressed this problem using a custom virus oligonucleotide array-based technology that can detect all known mammalian and avian pathogenic viruses.
- Each virus is represented by 10 or more features (both conserved and unique regions represented) to provide redundancy and also to allow the identification of new viruses that may arise via recombination.
- Human influenza and avian flu viruses are represented as tiling paths to aid in the identification of viral sub-types as well as the precise definition of influenza recombination events.
- Both RNA and DNA viruses are represented; Highly sensitive DNA virus 5-10 virus particles; RNA virus: 20-200 virus particles.

Some Key Points for Analysis of Viral Chips

- 1. Confounding issues and assumptions:
- The detected virus not necessarily is the causative virus for tumor or diseases, but a consequence of impaired immunity.
- Only a portion of the disease population got the intended virus
- > The control group has to be very "clean", no intended virus at all or to large extent
- For virus chip data of each sample, the strongest probe signals are not necessarily from the intended virus. Two-class contrast analysis helpful!
- 2. Multiple Probes (most of them >=10) in arrays are designed to detect the same virus.
- 3. Two class contrast : disease vs control. Sample-Level-Enrichment-Based Pathway Ranking Method (SLEPR)
- 4. Conventional gene-level array analysis methods not suitable for such tasks

5. Rationale for the analysis: Look for the virus detected by multiple probes with "good" signals, but with biggest contrast in between the two classes. "clean" Control samples are crucial.



Schematic Work Flow of Sample-Level Enrichment Based Pathway Ranking Method:

Yi and Stephens (2008) PLoS ONE 3(9):e3288) E: Exclusion Class I: Inclusion Class Step ' data distribution of G1 in class E G1 G2 G3 MADe samples(I+E) with Step 2 Median sample-level differenatiated gene as G1 data distribution get sample-level of G2 in class E differentiated genes for MADe Step 3 each samples samples(I+E) with Median sample-level L1 L2 L3 · · differentiated Batch compute enrichment gene as G2 of pathways/terms for Step 6) lists of all samples Step 4 Evaluate significance of Merge batch result into actual ranking against matrix of enrichment scores distribution of permutated Ranking Scores т1 Terms Ranking Scores P-Value Terms Ranking Scores т2 1.458956 0.000053 T103 1.458956 T103 тЗ T42 1.170402 T42 1.170402 0.000151 Pathway T101 0.695776 0.000967 T101 0.695776 Ranking **T**8 0.676175 **T8** 0.676175 0.001052 . Step 5 . Тx -0.542958 Тх -0.542958 0.997906



All 64 probes signals of human herpesvirus 4 (in Z-scores: reflecting relative expression level) in samples of Microarray #2



Samples having more probes with higher signals for human EBV (HHV4)



Higher Ranks	In	dividual Samr	ole Rank	king Data	
Sample2	6_CFS	Sample23	CFS	S27_Control	
Virus	ProbeNum	Virus	ProbeNum		Probe
Human herpesvirus 5	241	HHV8 long unique region, 80 putative ORE's and kaposin		Virus	Num
Human and aganous		gene, complete cds	77	Human herpesvirus 5	241
retrovirus clone M3.5	10	Human herpesvirus 5	241	Human endogenous retrovirus clone M3 5	10
Kaposi's sarcoma- associated		Human herpesvirus 4	64	Human endogenous reliovirus cione mo.o	10
herpesvirus long unique region, 80		Human endogenous retroviral DNA (4-1)	10	HHV8 long unique region, 80 putative ORF's and kaposin gene, complete cds	77
putative ORF's and kaposin gene, complete cds	77	Human endogenous retrovirus clone M3.5	10	Human herpesvirus 4	64
		Human herpesvirus 1	38	Human herpesvirus 2	39
segment 1	78	Equine herpesvirus 2	17	Human herpesvirus 1	38
Dengue virus type 1	10	Tick-borne encephalitis virus	10	Ictalurid herpesvirus 1	25
Simian-Human immunodeficiency		Human T- Iymphotropic virus 2	10	Equine herpesvirus 2	17
virus	10			Human herpesvirus 7	26
Influenza B virus (B/Memphis/12/97- MA) segment 5	56			Human endogenous retrovirus pHE.1 (ERV9)	10
Human T- Iymphotropic virus 1	12				
Influenza A virus segment 4 (H2)	58				

Lower Ranks

Top 7 viruses in 4 controls by individual ranking

Тор	S21_Control	S27_Control	S29_Control	S30_Control
1	Ictalurid herpesvirus 1	Human herpesvirus 5	Human herpesvirus 5	Human herpesvirus 5
2	Rubella virus	Human endogenous retrovirus clone M3.5	Kaposi's sarcoma- associated herpesvirus long unique region, 80 putative ORF's and kaposin gene, complete cds	Kaposi's sarcoma- associated herpesvirus long unique region, 80 putative ORF's and kaposin gene, complete cds
3	Avian adeno-associated virus ATCC VR-865	Kaposi's sarcoma- associated herpesvirus long unique region, 80 putative ORF's and kaposin gene, complete cds	Human herpesvirus 4	Human herpesvirus 4
4	Human T-lymphotropic virus 1	Human herpesvirus 4	Human herpesvirus 1	Human endogenous retrovirus clone M3.5
5	Human endogenous retrovirus pHE.1 (ERV9)	Human herpesvirus 2	Equine herpesvirus 2	Human herpesvirus 1
6	Human endogenous retrovirus clone M3.5	Human herpesvirus 1	Influenza A virus segment 1	Human herpesvirus 2
7	Adeno-associated virus 3B	lctalurid herpesvirus 1	Human herpesvirus 2	Ictalurid herpesvirus 1



Top 6 viruses of all 5 tumors in individual ranking Microarray #1



Class-Contrast-Based Ranking method lowered rank of HERV 4.1 from #1 to #1319

In Microarray #1, Human endogenous retroviral DNA (4-1) showed Up as top ranked virus in many CFS samples , however, it is also Highly ranked in many of the controls (ranked as top 9 in S21 and S29), which immediately reduced its significance using class-contrast-based ranking method Actually Put it into rank 1319



Human endogenous retroviral DNA (4-1)



Top 22 Viruses of SLEPR ranking result: Rank Result same as The result of Normalized Pooled Data

-3.0 1:1 101000 Jest laws in the interval of t

In SLEPR result, any thing shown in red: at least enrichment p<0.05 (ES score >1.3) and List Hits>=2 Lower Ranks

CMV and HHV7 : Top two ranking viruses in ME/CFS with clonal TCRg rearrangements

Higher Ranks

Human herpesvirus 5 Human herpesvirus 7 Feline leukemia virus Pestivirus type 1 Equine herpesvirus 1 Human adenovirus F Adeno-associated virus 4 Modoc virus Influenza A virus segment 4 (H5) Influenza A virus segment 1 Human herpesvirus 6B Influenza A virus neuraminidase gene (N4) Influenza A virus segment 5 Human herpesvirus 2 "La Crosse virus strain Human/78 segment M Theilovirus Mouse parvovirus 1 **Porcine enterovirus B** Macaca mulatta rhadinovirus Human adenovirus C Influenza A virus segment 4 (H1) Murine polyomavirus strain A2

<u>CONCLUSION</u>: CFS Patients expressed significantly higher levels of all viruses. CMV>HHV6>HHV7>EBV were identified as the most actively expressed herpes viruses in this CFS cohort. These data suggest that multiple highly active herpes virus infections distinguish CFS patients from healthy and underscore the role of the innate immune deficiencies in the pathogenesis of CFS.

TRANSLATION: FUTURE PLANS:

- We (The WPI and NCI) have developed a custom herpes virus 4, 5, 6A, 6B and 7 chip to quantify expression of each virus from same sample as a diagnostic tool. This chip will be licensed by VIPDx for clinical use.
- The herpes chip and cytokine signature diagnostic tools can be licensed by physicians world-wide to stratify patients monitor clinical trials of combinations of antiviral, immune modulating and anti-inflammatory drugs



Cytokine and Chemokine Profiling



Vincent C. Lombardi, PhD

Kathryn S. Hagen, MA

Darren C White

Daniel L. Peterson MD, Sierra Internal Medicine W. John Diamond MD, Triad Medical Center



Doug Redelman PhD Wei Yang, MD, PhD Julie Smith-Gagen, PhD The Patients and controls who graciously volunteered to participate!



Rationale:

≻Chronic Innate Immune activation by pathogenic triggers in a genetically susceptible host mediate the pathogenesis through a cytokine/chemokine storm.

>Multiplex suspension arrays afford the opportunity to analyze the complex relationships between the cytokines and clinical disease and to determine if clinical subgroups of disease could be identified based on distinct cytokine profiles

Clonal TCRg Rearrangement Testing CFS Cohort

RATIONALE:

Clonal TCRg Rearrangements:

- Suggest chronic active infection particularly CMV
- Predictive of lymphoma development

gd T cells :

- Play active role in regulation and resolution of pathogen induced immune responses
- Accumulate at sites of inflammation
- Associated with Viral, Parasitic and bacterial Infections
- Associated with autoimmune diseases
- Upregulate MIP1a, B, TNFa, IL-10, IFNg

Clinical Criteria for Testing:

- Acute (viral) onset CFS
- Lymphadenopathy and/or splenomegaly



Inflammatory Chemokines Previously Linked to Chronic Inflammatory Diseases are Up Regulated in ME/CFS

	INFLAMMATORY CHEMOKINES							
	Chemokine	Patient N = 118	Control N=138	P value				
CXC	IL-8	1045	13	<0.0001	RNAse L and CMV activated			
	MIG	48	80	<0.0001				
	IP-10	98	32	<0.0001	Interferon response protein			
CC	MCP-1	468	421	0.0003				
	MIP-1a	763	91	0.0062	Important in Neurodegenerative disese			
	MIP-1b	1985	164	<0.0001	Important in Neurodegenerative disese			
	RANTES	27107	9564	0.0018				
	EOTAXIN	271	96	<0.0001				

Mean values in pg/ml: Red denotes up regulation, Blue denotes down regulation



Shift of TH1, TH2 and TH17 Functional T-cell Subsets in ME/CFS

	FUNCTIONAL T-CELLS						
	Cytokine	Patient N = 118	Control N=138	P value			
TH ₁	IL-2	113	28	<0.0001			
	IFN-g	16	13	0.072			
	IL-12	289	211	0.0001			
TH	IL-4	40	55	0.0003			
	IL-5	7	21	<0.0001			
	IL-13	28	86	<0.0001			
	IL-10	70	49	0.56			
T _{reg}	CD-25	289	476	0.09			
TH ₁₇	GM-CSF	108	166	<0.0001			
	IL1B	500	56	<0.001			
	IL-6	336	29	<0.0001			
	TNF-a	148	13	<0.0001			



Mean values in pg/ml: Red denotes up regulation, Blue denotes down regulation

Other Dysregulated Cytokines in ME/CFS

OTHER CYTOKINES							
Cytokin e	Patient N = 118	Control N=138	P value	Function			
INF-a	35	60	<0.0001	stimulate both macrophages and NK cells to elicit an anti-viral response			
IL-1RA	20	14	<0.0001	modulates a variety of interleukin 1 related immune and inflammatory responses			
IL-7	160	60	<0.0001	stimulates proliferation of B and T lymphocytes and NK cells			

Mean values in pg/ml: Red denotes up regulation, Blue denotes down regulation



Cluster Analysis Reveals Distinct Subgroups





Random Forest Analysis

- The RF algorithm uses ensemble of unpruned classification or regression trees produced through bootstrap sampling of the training data and random feature selection in tree generation Cytokines and Chemokines
- Prediction is made by a majority vote of the predictions of the ensemble.
- The FR algorithm is uniquely suited for cytokine and chemokine analysis in that in can handle highly skewed cytokine and a chemokine value well and weighs the contribution of each cytokine or chemokine according to its relatedness with others.



Random Forest Predicts 5 Cytokine/Chemokine Signature of ME/CFS with 94% Specificity and Sensitivity



Random Forest Variable Importance

Random Forests Prediction Success.

Actual Class	Total Cases	Percent Correct	Control N=135	Patient N=121
Control	138	93.48	129	9
Patient	118	94.92	6	112



Genetic Profiling:



Cancer Inflammation **Program Carrington Lab SARA BASS Mary Carrington** Pat Martin Xiaojiang Gao Ying Qi Fuh-Mei Duh **Darlene Marti** Yalun Lui **Rasmi Thomas** Smita Kulkarni

Mike Dean Frank Ruscetti



Darren White Kathryn Hagen



Polymorphic immune response genes affect the level of host resistance against human disease. Functional and molecular genetic studies validate and clarify the nature of these associations.



The HLA class I molecules present peptides to T cells

T Cell Receptor (TCR)





No significant associations found for HLA-A (p < .05)

	Cases N=67	Controls N=97		
	% (N)	% (N)	OR	p value
A*26	11 (7)	4 (4)	2.91	0.11
A*31	6 (4)	5 (5)	1.25	0.74
A*03	25 (16)	25 (24)	1.04	1.00
A*68	10 (6)	9 (9)	1.03	1.00
A*23	6 (4)	6 (6)	1.03	1.00
A*02	46 (29)	45 (44)	1.03	1.00
A*24	17 (11)	25 (24)	0.64	0.33
A*01	25 (16)	35 (34)	0.63	0.22
A*11	10 (6)	15 (15)	0.58	0.34



No significant associations found for HLA-C

	Cases	Controls			
	N=67	N=97			
	70 (IN)	70 (IN)		p value	
C*16	8 (5)	3 (3)	2.56	0.27	
C*05	26 (17)	16 (15)	1.89	0.11	
C*06	25 (16)	18 (17)	1.50	0.33	
C*01	6 (4)	4 (4)	1.49	0.72	
C*12	12 (8)	11 (10)	1.19	0.80	
C*04	25 (16)	22 (21)	1.15	0.71	
C*02	14 (9)	14 (13)	1.01	1.00	
C*03	18 (12)	22 (21)	0.80	0.69	
C*08	5 (3)	7 (7)	0.61	0.74	
C*07	43 (28)	56 (53)	0.60	0.15	

_							
		4.1					
	■ HI A_R*⁄	A is assor	riated with i	increased si	uscentihilit	v to ME/CE	S
-		- 15 05500			useepusiin	y (0) (0) (0)	\mathbf{U}

	Cases N=67	Controls N=97		
	% (N)	% (N)	OR	p value
B*44	37 (23)	19 (18)	2.56	0.02
B*57	16 (10)	7 (7)	2.44	0.11
B*18	13 (8)	6 (6)	2.22	0.16
B*38	6 (4)	4 (4)	1.59	0.71
B*35	19 (12)	17 (16)	1.20	0.68
B*51	13 (8)	13 (12)	1.04	1.00
B*40	11 (7)	11 (11)	0.98	1.00
B*14	5 (3)	7 (7)	0.65	0.74
B*08	14 (9)	22 (21)	0.61	0.30
B*07	19 (12)	29 (28)	0.58	0.19
B*13	3 (2)	6 (6)	0.50	0.48
B*27	6 (4)	13 (12)	0.48	0.28
B*15	8 (5)	16 (15)	0.47	0.22



The association with B*44 does not appear to be subtype specific

		Cases	Controls		
		% (N)	% (N)	OR	p value
B*4402	yes	26 (16)	14 (13)	2.22	0.06
	no	74 (46)	86 (83)		
B*4403	yes	15 (9)	5 (5)	3.09	0.08
	no	85 (53)	95 (91)		





HLA Class I ligand binding groups for KIR





HLA-Cw group 1 homozygosity is protective. HLA-Cw group heterozygosity is associated with increased susceptibility.

	Cases	Controls		
	% (N)	% (N)	OR	p value
c1/c1	18 (12)	40 (37)	0.36	0.008
c1/c2	63 (41)	44 (42)	2.20	0.02
c2/c2	18 (12)	16 (15)	1.22	0.64



HLA Bw4 alleles are associated with increased disease susceptibility

	Cases	Controls		
	% (N)	% (N)	OR	p value
Bw4	79 (49)	64 (62)	2.13	0.05
Bw4 80T	48 (30)	35 (34)	1.74	0.10
Bw4 80I	39 (24)	40 (39)	0.94	0.87



Study Summary

- HLA-B*44 is significantly associated with susceptibility to ME/CFS (OR = 2.56, p = 0.02).
- There was no significant association with HLA-A or -C.
- HLA-Bw4, a ligand for KIR is associated with susceptibility (OR = 2.13, p = 0.05)
- HLA-Cw group 1 homozygosity was associated with protection (OR= 0.36, p = 0.008) while HLA-Cw group heterozygosity was associated with increased susceptibility to CFS (OR = 2.2, p = 0.02).
- We are currently analyzing 100 additional patients to verify these associations.



Conclusion

Taken together these data suggest that this systems biology approach is and effective strategy for the development of serum biomarkers to stratify subgroups of ME/CFS patients for appropriate antiinflammatory, immune modulating, antimicrobial and antiviral therapeutics

